CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs. Part of its strategy is to leverage its expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively and faster using its unique dual development approach. For more information, visit the company’s website at www.casipharmaceuticals.com.